Management of Patients With Recovered Systolic Function

详细信息    查看全文

• 作者：Anupam Basuray^a ; ^{Anupam.Basuray@ohiohealth.com" class="auth_mail" title="E-mail the corresponding author} ; James C. Fang^b ; ^{james.fang@hsc.utah.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ACEI ; angiotensin converting enzyme inhibitors ; ACM ; alcohol-induced cardiomyopathy ; AF ; atrial fibrillation ; BB ; beta blockers/beta blockade ; CABG ; coronary artery bypass grafting ; CCT ; chemotherapy-induced cardiomyopathy ; CRT ; cardiac resynchronization therapy ; CV ; cardiovascular ; HF ; heart failure ; ICD ; implantable cardioverter defibrillator ; ICM ; ischemic cardiomyopathy ; IDCM ; idiopathic dilated cardiomyopathy ; LV ; left ventricle or left ventricular ; LVAD ; left ventricular assist device ; LVE
• 刊名：Progress in Cardiovascular Diseases
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：58
• 期：4
• 页码：434-443
• 全文大小：517 K

文摘

Advancements in the treatment of heart failure (HF) with systolic dysfunction have given rise to a new population of patients with improved ejection fraction (EF). The management of this distinct population is not well described due to a lack of consensus on the definition of myocardial recovery, a scarcity of data on the natural history of these patients, and the absence of focused clinical trials. Moreover, an improvement in EF may have different prognostic and management implications depending on the underlying etiology of cardiomyopathy. This can be challenging for the clinician who is approached by a patient inquiring about a reduction of medical therapy after apparent EF recovery. This review explores management strategies for HF patients with recovered EF in a disease-specific format.